Kanjinti is a type of immunotherapy, not chemotherapy. It belongs to a class of drugs known as monoclonal antibodies, specifically designed to target and inhibit the HER2 protein, which is overexpressed in certain types of cancer cells. This targeted approach differentiates it from chemotherapy, which broadly attacks rapidly dividing cells.